← Eichor
Study identifier: NCT05675787 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Condition: Atypical Endometrial Hyperplasia · Endometrial Carcinoma Stage I  ·  Sponsor: Peking University People's Hospital

PhasePhase 2
Planned participants82
Who can joinFemale, 17 Years to 45 Years
Healthy volunteersNo

About this study

To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.

This description comes directly from the study's public registry record.

Talk to the study team

WANG JIANLIU, PhD/MD  ·  +861088324383  ·  wangjianliu1203@163.com

HE YIJIAO, PhD  ·  +8618301512017  ·  heyijiao2017@pku.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Wang JianliuBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05675787